AnnJi (7754) Fundamentals 2026 — Revenue Analysis | SniperIQ
AnnJi (7754) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT$5.7B, trading at NT$57.00 on the TWO. This SniperIQ fundamentals page covers AnnJi's valuation, profitability (net margin -4738.7%), revenue (NT$8M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is AnnJi's market cap?
AnnJi (7754) has a market capitalization of approximately NT$5.7B, trading at NT$57.00 on the TWO. Market cap moves with the live share price.
What is AnnJi's P/E ratio?
AnnJi's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 16.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is AnnJi?
AnnJi runs a net profit margin of -4738.7%, a gross margin of -282.1%, and an operating margin of -180.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does AnnJi generate?
AnnJi reported revenue of NT$8M for fiscal year 2025, with net income of -NT